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Summary  Progressive  multifocal  leukoencephalopathy  (PML)  is  a  rare  demyelinat-
ing  disease  caused  by  reactivation  of  a latent  JC  polyoma  virus.  The  ﬁrst  cases  of
PML  were  described  50  years  ago  in  patients  with  lymphoma.  PML  typically  occurs  in
immunocompromised  individuals,  particularly  those  infected  with  HIV.  We  present
a  52-year-old  male  with  lymphoma  who  was  treated  with  R-CHOP  (R:  Rituximab;  C:
Cyclophosphamide;  H:  Doxorubicin;  O:  Vincristine;  P:  Prednisone).  After  six  cycles
of  therapy,  the  patients  developed  tonic—clonic  seizure.  MRI  of  the  brain  showed
multiple  brain  lesions.  The  pathology  of  a brain  biopsy  was  diagnostic  for  PML.  We
review  radiographic  and  histopathological  features  of  the  disease.  The  literature  on
PML  and  its  association  with  immunosuppressant  agents  is  reviewed,  and  the  impact
of  rituximab  and  other  biological  agents  in  the  setting  is  highlighted.
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rogressive  multifocal  leukoencephalopathy  (PML)
s a  demyelinating  disease  of  the  central  nervous
ystem caused  by  the  JC  polyomavirus.  JC  virus
nfects  oligodendroglial  cells  almost  exclusively  in
nces. Published by Elsevier Limited. All rights reserved.
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focal leukoencephalopathy  (Fig.  3). During  his  stay,
he became  unresponsive  and  bedridden.  He  had
percutaneous  endoscopic  gastrostomy  (PEG)  tube494  
immunocompromised  patients,  including  those  with
AIDS, lymphoproliferative  disorders,  and  those  who
had chemotherapy.  The  occurrence  of  PML  in  rela-
tion to the  use  of  monoclonal  antibodies,  such
as natalizumab  and  rituximab,  has  been  reported
[1].  The  treatment  of  diffuse  cell  lymphoma  was
modiﬁed  in  the  last  decade.  Currently,  a  combina-
tion of  anti-CD20  monoclonal  antibody  (rituximab)
and cyclophosphamide,  doxorubicin,  vincristine,
and prednisone  (RCHOP)  chemotherapy  is  recom-
mended  [2].  The  use  of  R-CHOP  has  been  associated
with development  of  PML  [2]. The  exact  risk  of  PML
after monoclonal  antibody  use  was  quantiﬁed  in
relation  to  natalizumab.  It  was  estimated  that  the
overall risk  is  approximately  1.66  per  1000  patients
with multiple  sclerosis  treated  with  natalizumab
[3].  The  exact  risk  of  PML  in  patients  with  lym-
phoma  treated  with  R-CHOP  is  not  known.  In  this
study,  we  describe  a  patient  with  of  lymphoma  who
developed  PML  after  R-CHOP  and  presented  with
salient  features  of  the  disease.
Case presentation
The  patient  was  a  55-year-old  man  who  ﬁrst  pre-
sented  with  a  complaint  of  cough,  fever,  and
a 4-kg  weight  loss  over  eight  months’  dura-
tion. Physical  examination  was  signiﬁcant  for
right axillary  lymphadenopathy.  A  CT  scan  showed
hepatic  and  splenic  lesions  and  multiple  abdominal
lymphadenopathies.  The  patient  underwent  bone
marrow and  right  axillary  lymph  node  biopsies.
The pathology  showed  diffuse  large  B-cell  lym-
phoma with  bone  marrow  involvement  (stage  IV-B).
He received  R-CHOP.  The  patient  had  signiﬁcant
clinical improvement  on  R-CHOP  but  developed
prolonged neutropenia  which  required  several  hos-
pital admissions,  despite  the  use  of  granulocyte
colony stimulating  factors.  Following  additional
review, the  pathological  diagnosis  was  revised  to
nodular lymphocyte  predominant  Hodgkin’s  lym-
phoma;  however,  the  patient  was  continued  on  the
same regimen.  After  four  cycles  of  R-CHOP,  he  had
excellent  clinical  and  radiological  response  to  the
treatment.  The  ﬁfth  cycle  was  delayed,  as  the
patient did  not  appear  for  the  therapy  until  the  fol-
lowing month,  when  the  treatment  was  resumed.
After completing  six  cycles,  a  positron  emission
tomography (PET)-scan  showed  several  small  lymph
nodes in  the  mediastinum  and  in  the  lung  hilar
areas with  very  low  Standardized  Uptake  Values
(SUV) of  2.1  of  unknown  signiﬁcance.  A  month
later, he  was  admitted  with  seizure  activity.  A
CT scan  of  the  brain  followed  by  an  MRI  showed
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nigure  1  MRI  of  the  brain  showing  multifocal  cortical
nd  subcortical  periventricular  lesions  with  no  edema  and
o  enhancement.
ultiple  brain  lesions  (Figs.  1  and  2).  The  MRI  of  the
rain showed  multifocal  cortical  and  subcortical
eriventricular  lesions  with  no  edema  and  enhance-
ent. A  similar  lesion  was  noted  in  the  brainstem.
e was  initially  started  on  anti-bacterial  and  anti-
ungal treatment.  A  brain  biopsy  was  performed
ith a pathological  diagnosis  of  progressive  multi-igure  2  MRI  of  the  brain  showing  multifocal  cortical
nd  subcortical  periventricular  lesions  with  no  edema  and
o  enhancement.
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Figure  3  Brain  biopsy.  (A—C)  Dense  macrophage  inﬁltration  with  bizarre  astrocytes  featuring  large  hyperchromatic
nuclei  and  viral  inclusions  characterized  by  chromatin  margination  (hematoxylin  and  eosin  stain.  A:  10×,  B:  20×,  C:
40×).  (D)  Marked  decrease/loss  of  myelin  (neuroﬁlament  immunohistochemical  stain.  40×).  (E)  Relatively  normal  area
f in.  4
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nor  comparison  (neuroﬁlament  immunohistochemical  sta
nsertion.  Meﬂoquine  was  not  used  due  to  G6PD
eﬁciency.
istopathology of the Brian Biopsy
he  biopsy  was  composed  of  white  matter  which
howed dense  macrophage  inﬁltration  associated
ith myelin  loss.  The  presence  of  demyelina-
ion was  conﬁrmed  by  the  stains  for  LFB/PAS  and
euroﬁlament,  which  highlight  the  loss  of  myelin
ith  relative  axonal  preservation,  as  is  typical
f demyelination.  In  the  background,  there  was
vidence  of  bizarre  astrocytes  with  large  hyper-
hromatic nuclei,  as  well  as  more  typical  viral
nclusions characterized  by  chromatin  margination.
hese inclusions  were  well-highlighted  by  the  in-
itu hybridization  studies  for  John  Cunningham  (JC)
irus. On  CD3  and  CD20  stains,  a  moderate  number
f CD3  positive  T-lymphocytes  were  present.
iscussionn  recent  years,  monoclonal  antibodies  are  becom-
ng the  drugs  of  choice  for  many  rheumatological
iseases  and  inﬂammatory  conditions,  such  as
(
t
r0×).
nﬂammatory  bowel  disease  and  multiple  sclerosis.
he use  of  these  monoclonal  antibodies  is  associ-
ted with  several  infectious  diseases,  such  as  PML
1]. In  a study  of  30  patients  with  Crohn’s  dis-
ase who  were  prescribed  natalizumab,  no  patient
eveloped  PML  [4]. In  another  study  of 34  con-
rmed cases  of  PML  in  the  setting  of  autoimmune
heumatic diseases  (ARDs),  17  had  systemic  lupus
rythematosus,  10  had  rheumatoid  arthritis,  4
ad vasculitis,  and  3  had  dermatomyositis  [4].  In
nother study,  15  patients  were  treated  with  one
r more  biologic  agents,  and  14  received  ritux-
mab (RTX).  Six  received  anti-tumor  necrosis  factor
anti-TNF)  therapy,  and  of  those  patients,  ﬁve
eceived  an  anti-TNF  agent  prior  to  RTX  [5]. The
tudy concluded  that  there  is  a  possible  relation-
hip between  rituximab  and  PML  [5].  Natalizumab
as associated  with  fatal  progressive  multifocal
eukoencephalopathy  due  to  reactivation  of  JC
irus and  occurs  with  greater  frequency  in  patients
ith previous  JC  virus  infection  [6].  None  of  the
9 patients  with  Crohn’s  Disease  who  received
atalizumab treatment  for  a median  of  7  months
interquartile range,  3—21.5  months)  had  PML  [7].
There  was  a  concern  regarding  the  excre-
ion of  JC  virus  in  the  urine  of  patients  who
eceived biologic  agents.  Among  16  such  patients
496  J.A.  Al-Tawﬁq  et  al.
Table  1  A  summary  of  PML  cases  in  patients  treated  with  R-CHOP.
Age  Gender  Malignancy  Number  of  R-CHOP
cycles  prior  to
diagnosis
MRI  ﬁndings  CSF  PCR
for JC
virus
Activity  of
lymphoma
at
diagnosis
of  PML
Reference
55  M  Diffuse
large  cell
B-
lymphoma
8  Multiple
demyelination  in
anterior  ponto-
mesencephon
region  and  the
right  thalamus
Not done  Remission  [2]
74  F  Lymphoma  Symptoms  started
after  the  third
cycle,  received
additional  3  R-CHOP
cycles  and  diagnosis
was  after  3
additional  Rituximab
cycles
Two hyperintense
lesions
Negative  Active  [12]
48  F  Diffuse
large  cell
B-
lymphoma
5  Right  cerebellum  Positive  Remission  [13]
55  M  Lymphoma  6  Multifocal
cortical  and
subcortical
sion
Not  done  Remission  Current
case
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who  were  treated  with  Etanercept  (n  =  8),  inﬂix-
imab (n  =  4),  adalimumab  (n  =  1),  multiple  anti-TNF
agents  sequentially  (n  =  2)  and  Rituximab  (n  = 1),
only two  (12.5%)  patients  excreted  JC  virus  in  the
urine [8].  The  signiﬁcance  of  such  activation  was
not delineated.  In  contrast,  the  risk  of  PML  in  mul-
tiple sclerosis  and  natalizumab  was  correlated  with
the positive  JC  serology,  prior  use  of  immunosup-
pressants, and  increased  duration  of  natalizumab
treatment [9]. In  contrast,  in  HIV  positive  patients,
JC viremia  was  not  predictive  of  PML  [10]. Sub-
clinical reactivation  of  JC  virus  was  documented  in
multiple sclerosis  patients  who  were  treated  with
natalizumab  [11].  Those  patients  had  an  increase
in the  prevalence  of  JC  virus  in  the  urine  from  19%
to 63%  after  18  months  of  treatment  [11]. How-
ever, the  risk  of  PML  for  lymphoma  patients  requires
further  study.
The use  of  biologic  agents  in  patients  with  lym-
phoma is  less  documented  than  in  rheumatological
diseases.  A  74-year-old  woman  with  lymphoma
treated with  R-CHOP  developed  neurological  symp-
toms after  three  cycles  of  chemotherapy  [12].
The sixth  cycle  of  CHOP  chemotherapy  was  with-
held and  three  additional  cycles  of  rituximab  were
given. Subsequently,  a  brain  biopsy  showed  PML
and the  patient  rapidly  deteriorated  and  died  [12].
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 second  case  was  a  48-year-old  female  patient
ith diffuse  large  B-cell  lymphoma  treated  with
-CHOP  therapy.  During  the  ﬁfth  cycle  of  R-CHOP,
he had  progressive  neurological  symptoms.  Mag-
etic resonance  imaging  showed  hyperintensity  in
he right  cerebellar  hemisphere  on  T2-weighted
mages. In  contrast  to  the  ﬁrst  case  described
bove, polymerase  chain  reaction-based  tests  of
he cerebrospinal  ﬂuid  was  positive  for  JC  virus
13]. Another  patient  with  diffuse  large  B  cell  lym-
homa was  treated  with  R-CHOP  and  developed
ML [2].  Interestingly,  this  patient,  similar  to  our
atient, had  ﬂuorodeoxyglucose-positron  emission
omography  (FDG-PET/CT)  and  showed  the  total
emission  of  disease  [2]. A  summary  of PML  cases  in
atients treated  with  R-CHOP  is  shown  in  Table  1.
PML developed  after  six  cycles  of R-CHOP  in  the
resented  case.  In  HIV-negative  patients  treated
ith  rituximab  who  developed  PML,  the  median
ime from  ﬁrst  dose  of  rituximab  to  PML  diagnosis
as 16  months,  the  median  time  from  last  dose  to
ML diagnosis  was  5.5  months,  and  the  median  time
rom PML  diagnosis  to  death  was  two  months  [14].
n ﬁve  patients  with  lymphoid  malignancies,  those
atients  had  PML  after  a median  of  three  Brentux-
mab vedotin  doses  and  within  a  median  of  seven
eeks of  therapy  [15].
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[ML  in  a  patient  with  lymphoma  treated  with  rituxi
Similar  to  the  present  case,  the  neuroimaging
f PML  typically  shows  symmetric  or  asymmetric
ultifocal demyelination  with  no  mass  effect  and
o contrast  enhancement  [16]. The  presence  of
ontrast  enhancing  lesions  and  local  mass  effect
ere  described  in  PML  in  association  with  HIV
fter initiation  HAART  therapy  in  patients  with
ultiple  sclerosis  or  Crohn’s  disease  treated  with
atalizumab  and  in  the  case  of  post-immune  recon-
titution  inﬂammatory  syndrome  [16].
The occurrence  of  neurological  symptoms  in
atients with  lymphoma  who  receive  R-CHOP
hould direct  a  prompt  search  for  the  occurrence
f CNS  lesions,  such  as  PML.  Further  studies  are
eeded to  quantify  the  risk  and  identify  the  patients
or whom  rituximab  should  be  avoided.
unding
o  funding  sources.
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